Gem Aromatics (GEMAROMA)

FairStock Score: 20/100 — RISKY

Score breakdown: P/E: 0/3 · ROCE: 1/2 · Growth: 0/2 · Dividend: 0/1

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

At ₹168.65, Gem Aromatics is being priced as if the bad times are temporary, but I do not see evidence yet. The latest quarter has lost ₹5 Cr on net sales of ₹79 Cr, and reported profit growth is down a staggering 166.89%; sales are 18.53% lower. A business that cannot grow sales and is now losing money fails the first test I apply: does it deliver growing earnings without excessive leverage? The balance sheet is not the problem—debt/equity is 0.32 and ROCE at 19.43% shows the core assets can earn a decent return when conditions are normal. But a Piotroski F-score of 3/9 tells me the fundamentals are deteriorating, and no dividend means I get no income while waiting for a recovery. The P/E of 35.06 is meaningless with negative earnings momentum; I prefer to value a business on normalised earnings power. Book value of ₹139.81 means the stock is only 1.21 times book, which provides some downside cushion if the assets are genuinely worth book. Promoters hold 55.06%, so they carry significant interest, but ownership alone does not create an economic moat. Specialty chemicals can be a good business, but this one has no pricing power visible in the numbers right now. The stock has fallen from ₹349.60 to ₹168.65; the market has already repriced the cycle. I would put this on my watch list, not in my portfolio. I need to see at least two quarters of positive net profit, stabilising sales, and an improving F-score before I can call it a Graham bargain.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer